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Abstract Alzheimer’s disease (AD) is the most prevalent
neurodegenerative disease in the Western world and is char-
acterized by a progressive loss of cognitive functions leading
to dementia. One major histopathological hallmark of AD is
the formation of amyloid-beta plaques, which is reproduced in
numerous transgenic animal models overexpressing patho-
genic forms of amyloid precursor protein (APP). In human
AD and in transgenic amyloid plaque mouse models, several
studies report altered rates of adult neurogenesis, i.e. the for-
mation of new neurons from neural stem and progenitor cells,
and impaired neurogenesis has also been attributed to contrib-
ute to the cognitive decline in AD. So far, changes in
neurogenesis have largely been considered to be a conse-
quence of the plaque pathology. Therefore, possible alter-
ations in neurogenesis before plaque formation or in prodro-
mal AD have been largely ignored. Here, we analysed adult
hippocampal neurogenesis in amyloidogenic mouse models
of AD at different points before and during plaque progres-
sion. We found prominent alterations of hippocampal
neurogenesis before plaque formation. Survival of newly gen-
erated cells and the production of new neurons were already
compromised at this stage. Moreover and surprisingly, prolif-
eration of doublecortin (DCX) expressing neuroblasts was
significantly and specifically elevated during the pre-plaque
stage in the APP-PS1 model, while the Nestin-expressing
stem cell population was unaffected. In summary, changes in
neurogenesis are evident already before plaque deposition and
might contribute to well-known early hippocampal dysfunc-
tions in prodromal AD such as hippocampal overactivity.
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Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative
disease that leads to a progressive loss of cognitive functions
[reviewed in 1, 2]. The most prominent histopathological hall-
marks contributing to the cognitive decline are the formation
of amyloid-beta plaques and neurofibrillary tangles [reviewed
in 3, 4]. Whereas the mechanism of amyloid-beta plaque for-
mation is still not fully understood, it is widely accepted that
low molecular weight amyloid-beta aggregates such as oligo-
mers act as toxic agents harming synapses and neurons, lead-
ing to altered synaptic function, neuronal loss, massive neu-
roinflammation, and finally contribute to dementia [reviewed
in 5, 6]. Based on this, a number of transgenic AD animal
models have been generated to simulate the amyloid-beta
plaque burden found in humans and to study familial
Alzheimer’s disease forms (FAD) with their human relevant
genetic predispositions [7–9]. Two widely used AD mouse
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models are the single transgenic Tg2576 expressing the hu-
man APP with the Swedish mutation (Tg(HuAPP695.
K670N- M671L)2576) [10] and the double transgenic APP
Swedish PS1 dE9 mouse model, in which mice are expressing
APP and PS1 mutations associated with early-onset AD
forms, i.e. a chimeric mouse/human amyloid precursor protein
(Mo/HuAPP695swe) and a mutant human presenilin 1 (PS1-
dE9) both directed to CNS neurons under the prion protein
promoter [11, 12]. Whereas the Tg2576 mouse model is a
slow progressive mouse model developing amyloid-beta
plaques and deficits in learning and memory at 9–13 months
of age [10, 13], in the APP Swedish PS1 dE9 mouse model,
amyloid-beta plaques start to form between an age of 3–4 and
9 months in the cortex and hippocampus [14–17]. Cognitive
deficits in spatial working memory were observed starting
already with 3–5 months of age in the double transgenic
mouse model [reviewed in 18].
Adult hippocampal neurogenesis has been explored in the
context of AD [reviewed in 19], as alterations in neurogenesis
might contribute to cognitive dysfunctions in dementias, and
as stimulation of hippocampal neurogenesis might counteract
the cognitive decline [reviewed in 7, 20, 21]. In the adult
rodent and human hippocampus, new neurons are generated
and integrated into the hippocampal circuitry from so-called
neural stem- and progenitor cells (NPCs) that reside in the
subgranular cell layer (SGCL) of the dentate gyrus [22, 23,
24, 25, reviewed in 26]. Importantly, hippocampal
neurogenesis is crucially involved in learning and memory
[27, 28, reviewed in 29].
In AD and in animal models of AD, neurogenesis has been
analysed, however with somewhat controversial results
[30–33]. Nevertheless, the vast majority of studies report
about decreased neurogenesis in AD mouse models often co-
inciding with amyloid-beta plaque pathology [reviewed in 21,
34]. For example, adult hippocampal neurogenesis is de-
creased in mice overexpressing the human APP with the
Swedish mutation [31] but in mouse models harbouring the
APP and the PS1 mutated genes decreased levels of
neurogenesis [17] and increased levels of neurogenesis were
reported in mice developing memory impairments and pro-
gressive plaque pathology [35]. In contrast, neurogenesis
was found to be increased in the APP model expressing the
Swedish and Indiana mutation [30]. In human AD patients,
the number of cells expressing young immature neuronal
markers was elevated compared to age-matched healthy con-
trols [36]. The differences described might rely on the differ-
ent genotypes depending on the analysed AD mouse models,
on the different methods used to asses neurogenesis, and of
course, also on the different stages of progression of the dis-
ease or of the pathology [reviewed in 20, 21]. However, very
little is known about differences in neurogenesis at the begin-
ning of the disease or before the onset of amyloid-plaque
formation.
As there is increasing awareness for the importance of the
pre-symptomatic phase in neurodegenerative diseases in the
context of early diagnosis and of pathogenesis [reviewed in
37, 38], we investigated the temporal pattern of amyloid-beta
plaque deposition in the hippocampus and analysed corre-
sponding levels of adult hippocampal neurogenesis from very
early prodromal to severe stages of amyloid-beta plaque for-
mation in the APP Swedish PS1 dE9 mouse model and in the
slower progressing Tg2576 AD mouse model.
Experimental Procedures
Animals
We used female APP Swedish PS1 dE9 mice [reviewed in 12]
expressing a chimeric mouse/human mutant amyloid precur-
sor protein (Mo/HuAPP695swe) and a mutant human
presenilin 1 (PS1-dE9) both directed to CNS neurons under
the prion protein promoter (Jackson Laboratory, https://www.
jax.org/strain/005864). We analysed mice at 3, 10, and 13
months of age. Age-matched non-transgenics derived from
the APP Swedish PS1 dE9 breeding were used as control
animals (n = 6/group). Mice were housed at the University
Hospital Bonn—Clinical Neuroscience in groups under stan-
dard conditions at a temperature of 22 °C and a 12 h light/dark
cycle with ad libitum access to standard food and water.
Animal care and handling were performed according to the
Declaration of Helsinki and approved by local ethical com-
mittees. Transgenic female Tg2576 mice overexpressing hu-
man APP Swedish and wild type littermates at postnatal ages
of 3 and 5 months (n = 6/group) were housed at the
Medizinisch-Experimentelles Zentrum, University of
Leipzig, at 12 h light/12 h dark cycles with standard food
and water ad libitum. The use of experimental animals with
Tg2576 was approved by the Landesdirektion Sachsen (li-
cence 06/15).
Bromodeoxyuridine Injection
For histological analysis of cell survival and fate, APP
Swedish PS1 dE9 mice received intraperitoneal injections of
10 mg/ml of the thymidine analogue bromodeoxyuridine
(BrdU) (Sigma) at 50 mg/kg of body weight dissolved in
0.9 % NaCl solution daily on 5 consecutive days 4 weeks
before perfusion.
Perfusion and Tissue Processing
APP Swedish PS1 dE9 and Tg2576 animals were
anaesthetised and transcardially perfused for immunohisto-
chemistry as previously described [39, 40]. Following perfu-
sion, the brains were extracted and postfixed in 4 %
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paraformaldehyde (PFA), sodium phosphate buffer solution
(PBS, 0.1 M; pH = 7.4) over night at 4 °C. The brains were
cryoprotected and transferred into 30 % sucrose, 0.1 M sodi-
um phosphate buffer solution (pH = 7.4). Sagittal sections of
40 μm (APP Swedish PS1 dE9) and coronal sections of
30 μm (Tg2576) were cut on dry ice, using a sliding
microtome.
Immunohistochemistry
Fluorescence Immunohistochemistry was performed on free-
floating sections. Following washes of PBS (0.1M, pH = 7.4),
antigen retrieval was performed by steaming the sections for
15–20 min in citrate buffer (pH = 6.0, Sigma). For BrdU and
PCNA labelling, the following steps were performed: the
slices were incubated for 1 h at 65 °C in 50 % formamide
(Merck) diluted in saline sodium citrate (SSC; 0.3 M NaCl,
30mMNa3Ci, pH = 7.0, Sigma), washed in SSC, incubated in
2 MHCl (Merck) for 30 min at 37 °C, followed by incubation
in 0.1 M borate buffer (pH = 8.5) for 10 min at room temper-
ature (RT). Brain sections were washed in PBS and afterwards
blocked for 1 h in FSGB + T (1 % BSA, 0.2 % fish skin
gelatine and 0.1 % Triton X-100 in PBS, all from Sigma).
Incubation with primary antibodies was done over night at
room temperature (RT). The following primary antibodies
were used: rabbit anti-doublecortin (1:300, Cell Signaling),
goat anti-PCNA (1:300, Santa Cruz Biotechnology), mouse
anti-NeuN (1:500, Millipore), mouse anti-Nestin (1:300,
Abcam), rabbit anti-Iba1 (1:300, Wako), rat anti-BrdU
(1:500, AbD Serotec), rabbit anti-Olig2 (1:200, Millipore),
guinea pig anti-GFAP (1:500, Progen Biotechnik), mouse
anti-Abeta (1:1000, Covance).
On the next day, sections were extensively washed in PBS
and incubated for 3 h at RT in secondary antibodies diluted in
FSGB + T. The following secondary antibodies were used:
donkey anti-rabbit Alexa Fluor 568, donkey anti-mouse
Alexa Fluor 488, anti-mouse Alexa Fluor 568, donkey anti-
mouse Alexa Fluor 647, donkey anti-rat Alexa Fluor 488 (all
Invitrogen), donkey anti-goat Alexa Fluor 647 (Jackson
Immuno Research), donkey anti-guinea pig Alexa Fluor 647
(Dianova), all 1:1000.
Nucleus counterstaining was performed with 4′.6′-
diamidino-2-phenylindole dihydrochloride hydrate (DAPI
1 mg/mL, 1:2000, Sigma). For qualitative amyloid-beta
plaque staining, Thioflavin S (1 mg/mL, 1:625, Sigma) was
added to the secondary antibody solution. Sections were
washed in PBS after incubation with secondary antibodies
and tissue from old mice (>9 months) was additionally treated
with 0.2 % Sudan Black (Sigma) in 70% EtOH for 1–2min to
reduce the autofluorescence of lipofuscin in old tissue. After
this treatment, the sections were extensively washed in PBS
and mounted onto microscope glass slides (Superfrost Plus,
Thermo Scientific). Brain sections were cover slipped semi
dry in ProLong Gold Antifade Mountant (Life technologies)
or Fluorescence Mounting Medium (Dako).
Microscopy, Visualization and Image Processing
For microscopic analysis of the plaque area and analysis of
adult hippocampal neurogenesis, Confocal Laser Scanning
Microscopy was performed using a LSM 700 or LSM 710
from Zeiss. Representative images were obtained by orthogo-
nal projections (maximum intensity) and depicted in respec-
tive false colours using Zen 2012 blue edition software. For
quantification of the GCL volume, images of the dentate gyrus
were taken with an Olympus fluorescence microscope
(Olympus IX81).
Quantitative Analysis of Immunohistological Data
Volume Analysis of Dentate Gyrus Granular Cell Layer
To estimate changes in the volume of the dentate gyrus gran-
ular cell layer (GCL) betweenWTand APP Swedish PS1 dE9
animals, the DAPI and Thioflavin S stained area of the dentate
gyrus GCL from one tenth of the brain hemisphere was mea-
sured for each animal using ImageJ (1.47v). The GCL volume
for one hemisphere was calculated by multiplication with 10
(multiplication factor for whole brain hemisphere) and 40
(section thickness) for every animal (n = 3/group). Statistical
analysis was performed with GraphPad Prism 6.
Quantification of Amyloid-Beta Plaque Areas
Five plaques in the hippocampus and 5 plaques in the cortex
were analysed in three 10- and 13-month old APP Swedish
PS1 dE9 animals and the area of the amyloid-beta stained
plaque was measured using the LSM Image Browser software
(Version 4.2.0.121, Zeiss). Statistical analysis was done with
GraphPad Prism 6.
Quantification of Adult Hippocampal Neurogenesis
For the APP Swedish PS1 dE9 mouse model, all qualitative
and quantitative analysis were performed in the dorsal dentate
gyrus of the hippocampus of 40 μm sagittal sections. For
quantification, every tenth section (400 μm intervals) of one
brain hemisphere was selected from each animal (n = 6/
group), and per animal four randomly selected visual fields
of the DGs were analysed. Antibody-positive cell types were
counted and quantified in the GCL and SGCL. The number of
proliferating cells (PCNA+), neuroblasts (DCX+), stem cells
(Nestin+), microglia (Iba1+) and double positive cells were
assessed. Additionally, the number of BrdU+ cells and the
number of newly formed cells such as neuroblasts (BrdU+/
DCX+), neurons (BrdU+/NeuN+), oligodendrocytes (BrdU+/
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Olig2) and astrocytes (BrdU+/GFAP+) were quantified. The
corresponding tissue area, i.e. GCL and SGCL, was measured
and multiplied by 40 to obtain the tissue volume represented
in cubic micrometre. To assess cell densities, the total number
of counted cells per animal was divided by the dentate gyrus
volume and represented as cells/cubic millimetre.
For analysis of hippocampal neurogenesis in the Tg2576
animal model, six randomly picked visual fields of DGs per
animal of 30 μm coronal sections (−1.46 to −3.16 mm from
Bregma) were selected. The number of proliferating cells
(PCNA+), neuroblasts (DCX+) and double positive cells
(PCNA+/DCX+) was counted in the GCL and SGCL of the
dentate gyrus. The corresponding tissue area of GCL and
SGCL was measured and multiplied by 30 to obtain the tissue
volume represented in cubic micrometre. To assess cell den-
sities, the total number of counted cells was divided by the
dentate gyrus volume and represented as cells/cubic
millimetre.
All analysis were performed using the ImageJ (1.47v) soft-
ware. Statistical analysis was done with GraphPad Prism 6.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism 6
(GraphPad Software). Data were tested for normality using
the D’Agostino-Pearson omnibus normality test and outliers
were identified by Grubbs’ test. Values between two groups
were compared by the two-tailed unpaired Student’s t test for
normally distributed data. Comparison of multiple groups was
done by two-way analysis of variance (ANOVA) with Tukey
multiple comparison.
P values of p < 0.0001 (****) and p < 0.001 (***) were
considered most significant, p < 0.01 (**) highly significant,
and p < 0.05 (*) significant. Values were expressed as
means ± standard deviation (SD).
Results
Amyloid-Beta Plaques Increase in Size and Disrupt
the GCL of the Dentate Gyrus in APP Swedish PS1 dE9
Mice
We first aimed to determine the onset and the progression of
amyloid-beta plaque formation in the hippocampus of APP
Swedish PS1 dE9 mice, herein abbreviated APP-PS1 mice.
In this transgenic mouse model, Thioflavin S positive
amyloid-beta plaques are described to form at 3 months [17]
or at 4 months of age in hippocampal and cortical regions [14].
As the main scope of the present study was to focus on hip-
pocampal neurogenesis in relation to plaque progression, we
first analysed amyloid-beta plaque deposition in the
hippocampus by Thioflavin S staining at different ages of
the APP-PS1 animals.
Thioflavin S positive amyloid-beta deposits were detected
in the hippocampus of 4 months old APP-PS1 mice, whereas
3-month-old transgenic animals were mostly devoid of any
plaque deposits (Fig. 1a). In the Tg2576 AD mouse model,
brains were free of amyloid-beta plaques at 3 months of age,
sporadically, we observed small Thioflavin S positive plaque
deposits at 5 months, while prominent plaque load was evi-
dent from 8months on (data not shown). Amyloid-beta plaque
load increased with age and was more prominent in the 10-
month and even more in the 13-month-old APP-PS1 animals
(Fig. 1a). Quantitative analysis revealed that the size of indi-
vidual plaques, both in the hippocampus and in the cortex, still
increased between 10 and 13 months of age (Fig. 1b). Brains
of WT animals, regardless of age, were completely devoid of
any amyloid-beta plaque depositions (data not shown).
Since hippocampus atrophy is a hallmark of AD, we eval-
uated possible volume changes of the dentate gyrus GCL in
the hippocampus of the APP-PS1 mice. Whereas the 3- and
10-month-old animals did not display any differences in the
GCL volume, the 13-month-old AD animals showed a signif-
icantly decreased GCL volume compared to age-matchedWT
controls (Fig. 1c). Interestingly, with progression of plaque
pathology, we observed amyloid-beta plaques being located
in the GCL of the hippocampus perforating the dentate gyrus
structure (Fig. 1d). Thus, besides a general atrophy of the
GCL, amyloid-beta plaque formation in the GCL and associ-
ated loss of neurons might contribute to GCL volume changes
at late stages of AD pathology.
Taken together, small Thioflavin S positive amyloid-beta
plaques were observed to form at 4 months of age in the
hippocampus of APP-PS1 mice. With increased age,
amyloid-beta plaque load was significantly increased in the
hippocampus as well as in the cortex and amyloid-beta de-
posits were found to perforate the GCL structure most likely
contributing to neurodegenerative events along pathology.
Hyperproliferation of Immature DCX Positive
Neuroblasts at Pre-plaque Stages in APP-PS1 and Tg2576
Mice
Quantitative analysis of adult hippocampal neurogenesis in
the GCL and SGCL of the dentate gyrus in the APP-PS1 mice
and in Tg2576 mice was performed by immunohistochemis-
try. The rate of neurogenesis was determined by evaluating the
numbers of proliferating cells (PCNA+), neuroblasts (DCX+)
and proliferating neuroblasts (PCNA+/DCX+) at different time
points. Furthermore, the stem cell pool was analysed by quan-
tifying the numbers of Nestin+ cells.
As expected, the overall number of PCNA+ cells declined
with age in WT as well as in APP-PS1 mice, in particular
between 3 and 10 months of age (Fig. 2a). This age-related
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decline in the number of proliferating cells translated in a
reduced number of DCX+ cells in both genotypes (Fig. 2b).
Interestingly, while there was no difference in the proliferation
rate between WT and APP-PS1 mice at advanced age, i.e. 10
and 13 months, young (3 months old) APP-PS1 mice showed
a significantly higher number of proliferating cells in compar-
ison to WT animals (Fig. 2a). This, however, did not lead to a
higher number of DCX positive cells (Fig. 2b). Surprisingly,
the numbers of PCNA+ cells co-expressing DCX (PCNA+/
DCX+) were significantly increased in 3-month-old APP-
PS1 animals compared to WT (Fig. 2c). Most of these prolif-
erating neuroblasts were located in the SGCL and displayed
an immature neuroblast morphology (Fig. 2c, arrow). This
hyperproliferation of neuroblasts was not detected at later
stages, i.e. 10 and 13 months of age, and can be considered
as an early event prior to amyloid-beta plaque formation. We
further investigated if the hyperproliferation of the DCX cells
affected the stem cell pool in the 3 months old APP-PS1
animals by analysing the Nestin+ cell population. The number
of Nestin+ stem cells and the number of PCNA+/Nestin+ cells
was unchanged in 3-month-old AD andWTanimals (Fig. 2d),
suggesting that the stem cell niche was not depleted as a con-
sequence of hyperproliferation.
The findings of hyperproliferation (PCNA+ cells) and
hyperproliferating neuroblasts (PCNA+/DCX+) at very early
stages in the APP-PS1 mice were confirmed in the Tg2576
ADmouse model. Here, adult hippocampal neurogenesis was
analysed at two time points prior to plaque formation, i.e.
in 3- and 5-month-old animals. Very similar to the APP-
PS1 mice, the number of PCNA+ cells was significantly
increased in 3-month-old Tg2576 animals compared to
WT, whereas at 5 months of age this effect had already
vanished (Fig. 2e). Similar to the APP-PS1 mice, the
number of DCX+ cells was unchanged in Tg2576 com-
pared to WT animals; however, the number of PCNA+/
DCX+ cells was significantly increased in 3-month-old
Tg2576 mice compared to WT. This hyperproliferation
of neuroblasts diminished very rapidly and was not detect-
ed in 5-month-old Tg2576 animals.
Taken together, we observe early changes in adult hippo-
campal neurogenesis by terms of increased proliferation and
increased numbers of proliferating neuroblasts prior to
amyloid-beta plaque formation in two different mouse models
for AD.
Reduced Cell Survival and Decreased Numbers of Newly
Formed Neurons in 3-Month-Old APP-PS1 Animals
Next, we determined if the prominent hyperproliferation of
DCX+ cells observed at the 3-months pre-plaque age trans-
lates into changes in cell survival and differentiation fate.
Therefore, we analysed the survival rate and cell fate of the
newly formed cells in the hippocampus of 3-month-old APP-
PS1 mice. Animals received BrdU at 5 consecutive days
Fig. 1 Development of amyloid-beta plaques in the hippocampus of
APP-PS1 mice at different time points of AD progression. a Amyloid-
beta plaques are first observed in the hippocampus of APP-PS1mice at an
age of 4 months and increased in number over time. b The area of Abeta
antibody immunoreactive plaques significantly increased in the hippo-
campus of 13-month-old compared to 10-month-old AD animals. The
same increase in amyloid-beta plaque load was observed in the cortex.
c Analysis of the GCL volume in the dorsal dentate gyrus of the
hippocampus revealed significantly decreased GCL volume specifically
in 13-month-old APP-PS1 mice compared to WT (unpaired Student’s t
test, p = 0,0213). d With progression of Abeta pathology, amyloid-beta
plaques appear in the GCL of the dentate gyrus perforating the healthy
tissue structure. Arrows show amyloid-beta plaques stained with
Thioflavin S. DAPI was used to stain cell nuclei. Two-way ANOVAwith
Tukey’s multiple comparisons test (b) and unpaired Student’s t test (c)
was performed (n = 3/group). Scale 200 μm (a), 100 μm (d)
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starting 30 days before perfusion, and survival and fate of
proliferating cells (BrdU+ cells) in the DG was analysed by
co-staining with markers for neuronal progenitors (BrdU+/
DCX+), newly formed neurons (BrdU+/NeuN+), astrocytes
(BrdU+/GFAP+) and oligodendrocytes (BrdU+/Olig2+)
(Fig. 3a).
Interestingly, in contrast to the hyperproliferation, the num-
ber of BrdU+ newly formed cells surviving the period of
30 days was significantly reduced in APP-PS1 compared to
WT mice (Fig. 3b). Analysis of cells committed to the neuro-
nal lineage (BrdU+/DCX+; BrdU+/NeuN+) revealed that after
30 days of BrdU injection, most of these previously dividing
cells were already differentiated into NeuN+ new neurons
(WT = 58,23 %; APP-PS1 = 39.06 %). The number of
BrdU+/DCX+ cells was very low (WT = 9.93 %; APP-
PS1 = 7.34 %), and did not differ significantly between
APP-PS1 and WT animals. In contrast, the number of newly
formed neurons (BrdU+/NeuN+ cells) in APP-PS1 animals
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was significantly reduced compared to WT (Fig. 3b, c).
Analysis of the glial lineage did not show any changes in the
number of BrdU+/Olig2+ or BrdU+/GFAP+ cells between
APP-PS1 and WT animals (Fig. 3b, c). Interestingly, when
analysing the potential fate of the BrdU+ cells, we noticed that
APP-PS1 mice showed a decreased percentage of BrdU+/
NeuN+ cells and a bigger pool of BrdU+ cells (BrdU+ only)
that did not co-localize with any of the neuronal or glial line-
age markers analysed (Fig. 3c).
Another cell type showing a considerable amount of pro-
liferation in the adult brain, in particular under pathological
conditions, is microglia. To test if microglia contribute to the
observed hyperproliferation in 3-month-old APP-PS1 mice,
we quantified the number of microglia (Iba1+) and proliferat-
ing microglia (PCNA+/Iba1+) in the GCL and SGCL of the
dentate gyrus in 3-month-old APP-PS1 and WT animals. The
numbers of Iba1+ cells and PCNA+/Iba1+ cells, the latter being
extremely low, were not different in 3-month-old APP-PS1
compared to WT animals (Fig. 3d), suggesting that the ob-
served increase in PCNA+ proliferating cells in 3-month-old
APP-PS1 mice was not due to increased microglia
proliferation.
Summarizing these observations, we conclude that in the
hippocampal neurogenic niche of 3-month-old APP-PS1
mice, even though amyloid-beta plaques are not yet present,
the survival of proliferating cells and their neuronal
differentiation fate is significantly reduced in APP-PS1 com-
pared to WT mice.
Discussion
The present work demonstrates early alterations in hippocam-
pal neurogenesis in two different amyloidogenic animal
models of AD, the APP Swedish PS1 dE9 and the Tg2576
mice. Surprisingly, even before the appearance of any visible
amyloid-beta plaques, neurogenesis was already affected. We
noticed a strong hyperproliferation of DCX expressing
neuroblasts specifically at the pre-plaque stage of pathogene-
sis. This, however, did not translate into a net increase in
neurogenesis, as the survival of the newly generated cells
was compromised already at this stage of pathogenesis.
Even though this is purely speculative at this point, a surplus
of hyperproliferating neuroblasts in the dentate gyrus might
have functional consequences for the hippocampal network. It
is well established that immature neurons in the adult hippo-
campus are electro-physiologically active, they are highly ex-
citable and modulate the activity of the hippocampal circuitry
[reviewed in 41–43]. Moreover, they are required for learning
as their depletion in an experimental animal model abolishes
the successful acquisition of spatial and reversal learning [27].
One might speculate that the surplus of young proliferating
immature neurons in the hippocampus at this pre-plaque stage
might relate to well-known alterations of hippocampus func-
tion in prodromal AD in humans such as hippocampal over-
activity as determined by functional MRI [44, 45]. An over-
activity of the hippocampus at early stages of AD resulting in
amnestic mild cognitive impairment (aMCI), is a dysfunction-
al condition being responsible for episodic memory loss in
patients [46–48]. Treatment of aMCI patients with the anti-
epileptic drug levetiracetam reduced the hippocampal hyper-
activity to levels of healthy controls and even improved their
memory function in memory tasks [49]. It is very likely that
hyperactivity of the hippocampus in prodromal AD stages is
consolidated or even provoked by changes in neurogenesis
such as increased proliferation of DCX expressing neuroblasts
in the dentate gyrus. Alternatively, the hyperproliferation of
DCX cells might relate to the increased seizure activity early
in human AD and in AD mouse models [50, 51]. Video EEG
recording of 3- to 4-month-old APP Swedish PS1 dE9 mice
revealed 65 % of AD animals developing at least one
electrographic seizure, with higher incidence at more ad-
vanced age [52]. Either the hyperproliferation of neuroblasts
might change hippocampal circuitry and contribute to sei-
zures, or vice versa, the seizures might induce a
hyperproliferation of the DCX cells. Indeed, seizures are well
known to increase hippocampal progenitor proliferation
and the number of DCX expressing neuroblasts [53, 54,
reviewed in 55].
Fig. 2 Hyperproliferation of immature DCX positive neuroblasts at early
stages of Abeta pathology in transgenic animal models. Quantitative
analysis of adult hippocampal neurogenesis in the GCL and SGCL of
the dentate gyrus in APP-PS1 and Tg2576 mice was performed by im-
munohistochemical staining for proliferating cells (PCNA+), neuroblasts
(DCX+) and proliferating neuroblasts (PCNA+/DCX+) at different time
points of Abeta pathology progression. a While PCNA+ cells decrease
with age from 3 to 10 months in both WTand TG, the 3-month-old APP-
PS1 animals showed a significant increase in the number of PCNA+ cells
compared toWT. b The number of DCX+ cells was not changed between
WT and APP-PS1 mice in any age group; however, both showed de-
creased DCX+ cell numbers with increased age. c The 3-month-old
APP-PS1mice had significantly elevated numbers of PCNA+/DCX+ cells
compared to WT animals. This effect was limited to the early stage of
Abeta pathology and was not seen in the 10- or 13-month-old animals.
These proliferating DCX+ cells were mainly located in the SGCL and had
small horizontal processes representing an immature neuroblast morphol-
ogy (insert with arrow). d Analysis of Nestin+ stem cells and PCNA+/
Nestin+ stem cells specifically in 3-month-old animals showed no chang-
es in the Nestin+ stem cell pool of APP-PS1 animals compared to WT. e
Analysing the Tg2576 mouse model at early stages of pathology con-
firmed the findings in the APP-PS1mousemodel. At 3 months of age, the
Tg2576 mice showed significantly increased numbers of PCNA+ cells
and significantly increased numbers of PCNA+/DCX+ cells compared to
WT mice. However, these changes were diminished in 5-month-old
Tg2576 animals. The number of DCX+ cells was not changed in 3- and
5-month-old Tg2576 compared to age-matched WT animals. NeuN was
used to stain granular mature neurons and DAPI was used as nucleus
stain. Two-way ANOVA with Tukey’s multiple comparisons test was
performed (a, b, c, e, n = 6/group; d, n = 5/group). Scale bar 100 μm
(a, b, c, d)
R
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The present study complements a number of previous stud-
ies that had analysed adult hippocampal neurogenesis in dif-
ferent mouse models for AD, however with controversial re-
sults [reviewed in 19]. Conclusive evidence for decreased or
increased neurogenesis in AD mouse models is not easily
possible, taking into account the different ages of analysed
mice cohorts studied, their individual genotypes
corresponding to the mouse model, and the specific analysed
cell populations in the different neurogenic niches.
Nevertheless, the majority of studies report about decreased
neurogenesis in AD mouse models [reviewed in 34]. In the
APP Swedish PS1 dE9 animals, reports were mainly on ani-
mals with already settled amyloid-beta plaque formation and
these studies mostly concluded a reduction in neurogenesis.
Fig. 3 Cell survival and cell fate analysis in the hippocampal neurogenic
niche of 3-month-old APP-PS1 mice 30 days after BrdU injection re-
vealed decreased numbers of newly formed neurons. a Representative
immunohistochemistry images of cell survival and fate analysis showing
cell survival (BrdU+), newly formed neuronal progenitors (BrdU+/
DCX+), neurons (BrdU+/NeuN+), astrocytes (BrdU+/GFAP+) and oligo-
dendrocytes (BrdU+/Olig2+) in the GCL and SGCL of the dentate gyrus.
bQuantification of cell survival revealed significantly decreased numbers
of BrdU+ cells and analysis of newly formed neurons showed specifically
decreased numbers of BrdU+/NeuN+ cells in 3-month-old APP-PS1 ani-
mals compared to WT. No changes were observed in the numbers of
BrdU+/DCX+, BrdU+/Olig2+ or BrdU+/GFAP+ cells. c The percentage
of BrdU+ cells that differentiated into new neurons (BrdU+/NeuN+) was
clearly reduced in 3-month-old APP-PS1 animals compared to WT (each
pie represents 100 % of BrdU+ cells). Interestingly, the percentage of
BrdU+ cells that did not co-localize with any of the neuronal or glial
marker examined (BrdU+ only) was increased in the APP-PS1 animals
compared to WT. d The number of microglia (Iba1+) and the number of
proliferating microglia (PCNA+/Iba1+) did not change in 3-month-old
APP-PS1 animals compared to WT. White lines indicate GCL and
SGCL of the dentate gyrus. Two-way ANOVA with Tukey’s multiple
comparisons test was performed for the neuronal and the glial lineage
(b, n = 4/group) and for microglia (d, n = 5/group). Scale bars 50 μm (a),
100 μm (d)
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Taniuchi et al. describe lower cell proliferation, i.e. reduced
BrdU+ cell numbers after 3 days of consecutive BrdU injec-
tion, and reduced numbers of neuroblasts (DCX+ cells) in 9-
month-old APP Swedish PS1 dE9 animals [32], i.e. the same
model as in the present study. Additionally Taniuchi et al.
analysed 5-month-old APP-PS1 animals; however, they did
not observe any changes in neurogenesis at this age. Niidome
et al. showed decreased numbers of proliferating cells (BrdU+
cells) in the SGCL of 9-month-old APP Swedish PS1 dE9
mice [58]. In contrast, the present analysis did not reveal
changes in dentate gyrus cell proliferation or in the number
of neuroblasts in 10-month-old APP Swedish PS1 dE9 ani-
mals, i.e. a stage with severe plaque pathology. This might be
due to the different methods used to detect cell proliferation.
We analysed proliferation by the cellular expression of PCNA,
a protein expressed by proliferating cells in late G1 and S-
phase of mitosis [59]. Others used BrdU labelling as a prolif-
eration marker, which, depending on the time between cell
labelling and animal perfusion, can provide different results.
At the level of survival and fate of the newly generated cells,
Verret et al. report reduced cell survival, i.e. the number of
BrdU+ cells that were labelled 4 weeks before, and reduced
numbers of newly formed neurons (BrdU+/NeuN+ cells) in the
hippocampal dentate gyrus of 6-month-old double transgenic
APP Swedish PS1 dE9 mice, which at this stage have already
prominent amyloid-beta plaque depositions in the hippocam-
pus [60]. We demonstrate that the reduction of cell survival
and formation of new neurons is evident already early in the
development of Abeta pathology, prior to amyloid-beta plaque
formation. This is consistent with the work by Demars et al.,
which describes reduced neuronal differentiation in 2-month-
old APP Swedish PS1 dE9 animals [61].
The changes in neurogenesis at the pre-plaque stage were
not restricted to the APP Swedish PS1 dE9 animals but also
evident in the slower disease progression Tg2576 model. This
is in agreement with the work by Krezymon et al., which
describes increased numbers of proliferating cells in the hip-
pocampus of 3-month-old Tg2576 mice [33]. Furthermore,
Krezymon et al. showed decreased numbers of newly formed
neurons (BrdU+/NeuN+ cells) at this very early stage in the
Tg2576 mouse model. The newly formed neurons had shorter
and less arborized dendrites, fewer dendritic spines, and
shorter axons and were not integrated into the hippocampal
circuitry ultimately leading to a reduced survival of these cells
[33].
What triggers the early changes in neurogenesis?
Obviously, amyloid-beta forms might induce changes in
the activity of hippocampal neural stem- and progenitor
cells or even in the newly generated neurons. Soluble
amyloid-beta peptides at low concentrations have a trophic
effect and promote the survival of neurons [62]. Also, other
proteolytic products from APP, e.g. the sAPPalpha prod-
uct, stimulate proliferation of adult SVZ NPCs [63]. The
effects of amyloid-beta and its different forms on neural
stem cells (NSCs) are still controversial [reviewed in 21,
64]. For example, only aggregated amyloid-beta1–42 was
able to induce neurogenesis in vitro. Thereby it is not af-
fecting proliferation of murine NSCs; however, it increased
the number of total neurons in vitro. Interestingly, only
aggregated amyloid-beta1–42 and oligomeric amyloid-beta
forms were able to increase neurogenesis in vitro, whereas
non-aggregated forms of amyloid-beta1–40 or amyloid-be-
ta1–42 had no effect on the NSC cultures [65]. Another
report demonstrates that amyloid-beta oligomers reduce
proliferation of human neural stem cells and alter the fate
of the newly generated cells from neuronal towards the
glial lineage [66]. Fibrillary amyloid-beta forms are heavi-
ly discussed to reduce neurogenesis in vitro. Human em-
bryonic stem cell cultures and respective neurosphere cul-
tures either treated with fibrillary amyloid-beta or condi-
tioned media of human microglia treated with fibrillary
amyloid-beta decreased neuronal differentiation and
switched differentiation towards glial cells in vitro [67].
In vivo, human amyloid-beta1–42 injected into the hippo-
campus of adult mice inhibited neurogenesis [68]. Thus,
the effect of amyloid-beta on neurogenesis is still contro-
versial [reviewed in 7].
The increase in the number of proliferating neuroblasts is
not limited to the prodromal stages of AD pathology but is
also seen in other neurodegenerative diseases suggesting that
other non-APP specific factors might contribute tomodulation
of neurogenesis in neurodegeneration. In rat models for
Huntington disease, an increased number of proliferating
neuroblasts can be detected at early stages of disease as well
[69]. Also, in alpha-synuclein transgenic models for
Parkinson’s disease (PD), similar findings of reduced cell sur-
vival and reduced new neuron numbers are reported in 4-
month-old mice, before PD symptoms are observed [70]. A
mechanism common to the various neurodegenerative dis-
eases modulating neurogenesis might be neuroinflammation,
in particular microglia activity [reviewed in 71].We addressed
this issue in the present work, but did not see any changes in
the number of microglia or in the number of proliferating
microglia.
Prodromal changes in neurogenesis are described in
a variety of neurodegenerative diseases. Therefore,
adult hippocampal neurogenesis is a process that is
highly sensitive to changes and is already reflecting
very early changes to the brains microenvironment.
Our findings suggest that first changes of the neuro-
genic niche environment occur at very early prodromal
stages of Abeta pathology and these alterations already
have an impact on cell proliferation, cell survival and
cell fate. Further investigation in particular on the
functional relevance of the hyperproliferating DCX
cells will be required.
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